Elvitegravir
From Self-sufficiency
Revision as of 01:13, 11 September 2010 by حسن علي البط (Talk) (Adding category Category:Organofluorides (using HotCat))
| File:Elvitegravir.png | |
| File:Elvitegravir3D.PNG | |
| Systematic (IUPAC) name | |
|---|---|
|
6-[(3-Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid | |
| Identifiers | |
| CAS Number | 697761-98-1 |
| ATC code | none |
| PubChem | CID 5277135 |
| Chemical data | |
| Formula | C23H23ClFNO5 |
| Molar mass | 447.883 g/mol[[Script error: No such module "String".]] |
Elvitegravir (EVG) is an investigational new drug for the treatment of HIV infection. It acts as an integrase inhibitor. It is undergoing Phase III clinical trial[1] conducted by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2005.[2][3][4]
According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.[5]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />| 50px | This antiinfective drug article is a stub. You can help ssf by expanding it. |
- ↑ Gilead Press Release Phase III Clinical Trial of Elvitegravir July 22, 2008
- ↑ Gilead Press Release Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor March 22, 2005
- ↑ Shimura K, Kodama E, Sakagami Y; et al. (2007). "Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137)". J Virol. 82 (2): 764. doi:10.1128/JVI.01534-07. PMC 2224569 Freely accessible. PMID 17977962.
- ↑ Stellbrink HJ (2007). "Antiviral drugs in the treatment of AIDS: what is in the pipeline ?". Eur. J. Med. Res. 12 (9): 483–95. PMID 17933730.
- ↑ Thaczuk, Derek and Carter, Micheal. ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents Aidsmap.com. 19 Sept. 2007.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Integrase inhibitors
- Quinolines
- Organochlorides
- Organofluorides
- Antiinfective agent stubs
- 2Fix
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
